Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that two E-posters will be presented at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE) beginning today in Nashville, Tennessee until May 17, 2026.

The data to be presented include two comparative analyses of VDPHL01's Phase 2 male data results versus published data on the efficacy of existing minoxidil formulations. The first is a blinded, retrospective investigator global assessment in which nine independent dermatologists evaluated the perceived efficacy of VDPHL01 at 2 and 4 months in males against 6-month male data on immediate-release oral minoxidil and topical minoxidil. The second leverages Global HairMap™ (SOCAi), an AI-based platform, to retrospectively compare androgenetic alopecia (AGA) outcomes of VDPHL01 at 4 months against males receiving immediate-release oral minoxidil for 6 months.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.